Results 51 to 60 of about 1,327 (186)

Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial

Neurology and Therapy, 2023
Introduction There have been no prior trials directly comparing the efficacy of different calcitonin gene-related peptide (CGRP) antagonists for migraine prevention.
Todd J. Schwedt, Tina M. Myers Oakes, James M. Martinez, Bert B. Vargas, Hitendra Pandey, Eric M. Pearlman, Diane R. Richardson, Oralee J. Varnado, Michael Cobas Meyer, Peter J. Goadsby   +9 more
doaj   +1 more source

A phase 1 study of the breast milk and plasma pharmacokinetics of zavegepant 10 mg intranasal dose in healthy lactating women

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study evaluated the pharmacokinetics of zavegepant in human breast milk and plasma following a single, 10 mg dose of zavegepant nasal spray. Background Zavegepant nasal spray is a member of the gepant class of medications; small molecule inhibitors of the calcitonin gene‐related peptide receptor.
Abhijeet Jakate, Yan Weng, Ani Shkrodova, Ogert Fisniku, Ding Ding, Kayce Morton, Benjamin Maligalig, Pamela Garnick, Jing Liu, Mohamed H. Shahin   +9 more
wiley   +1 more source

Novel optimization of multi‐mechanistic approaches for the acute treatment of a migraine attack: A review

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To highlight key factors required to optimize multi‐mechanistic approaches with oral combination treatments for the acute management of a migraine attack. Background Given the complex multi‐factorial nature of migraine, combining treatments with different mechanisms of action should improve outcomes compared to monotherapies, but ...
Stephen Silberstein, Alan M. Rapoport
wiley   +1 more source

Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial

The Journal of Headache and Pain
Background Rimegepant orally disintegrating tablet (ODT), an oral small-molecule calcitonin gene-related peptide receptor antagonist, is indicated for acute and preventive treatment of migraine in the United States and other countries.
Shengyuan Yu, Aihong Guo, Zhen Wang, Jianguang Liu, Ge Tan, Qian Yang, Mingjie Zhang, Hasiyeti Yibulaiyin, Huisheng Chen, Yongbo Zhang, Robert Croop, Yanhui Sun, Yu Liu, Qian Zhao, Zhihong Lu   +14 more
doaj   +1 more source

Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults

Clinical and Translational Science
A single‐center, phase I, partially double‐blind (double‐blind regarding doses of rimegepant and placebo, and open label with respect to moxifloxacin), randomized, 12‐sequence, four‐period crossover study of therapeutic (75 mg) and supratherapeutic (300 ...
Rajinder Bhardwaj, Michael S. Hanna, Beth A. Morris, Kyle T. Matschke, Richard Bertz, Robert S. Croop, Jing Liu   +6 more
doaj   +1 more source

Delayed urticaria during treatment with anti‐CGRP monoclonal antibodies in migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To characterize clinical presentation and management of urticaria associated with calcitonin gene‐related peptide (CGRP) ‐targeting monoclonal antibodies (mAbs) for migraine prophylaxis. Background CGRP‐targeting mAbs are effective in migraine prophylaxis, but have been associated with hypersensitivity reactions, including urticaria.
Christoph T. Berger, Federico Burguet Villena, Severin B. Vogt, Lukas Heydrich, Karin Hartmann, Athina Papadopoulou   +5 more
wiley   +1 more source

Calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraines in adults

Drugs in Context, 2022
Migraine headaches are widespread, debilitating and considered a main cause of disability worldwide. Symptoms of migraines include unilateral, pulsating pain that can last for hours to days, frequently associated with photophobia and phonophobia, nausea,
Eric R Ocheretyaner, Maria Kofman, Elaena Quattrocchi   +2 more
doaj   +1 more source

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To compare the 3‐month effectiveness of galcanezumab with select traditional oral migraine preventive (TOMP) medications recommended by scientific societies (TOMP efficacy subset) and with the most frequently used individual TOMP medications.
Shivang Joshi, Cristina Tassorelli, Manjit Matharu, Taoufik Alsaadi, Carlos Vallarino, Lars Viktrup, Maurice Vincent, Rebecca L. Robinson   +7 more
wiley   +1 more source

International Headache Society global practice recommendations for the acute pharmacological treatment of migraine [PDF]

Background: In an effort to improve migraine management around the world, the International Headache Society (IHS) has here developed a list of practical recommendations for the acute pharmacological treatment of migraine.
Al-Khazali, Haidar M., Ashina, Messoud, Ashina, Sait, Burstein, Rami, Chu, Min Kyung, Cipriani, Andrea, Cocores, Alexandra, Diener, Hans-Christoph, Dodd-Glover, Freda, Ekizoğlu, Esme, Garcia-Azorin, David, Goicochea, Maria Teresa, Göbel, Carl, Hassan, Amr, Hirata, Koichi, Hoffmann, Jan, Jenkins, Bronwyn, Kamm, Katharina, Lee, Mi Ji, Liebler, Eric, Ling, Yu-Hsiang, Lisicki, Marco, Martinelli, Daniele, Monteith, Teshamae S., Ornello, Raffaele, Ozge, Aynur, Peres, Mario, Pozo-Rosich, Patricia, Puledda, Francesca, Romanenko, Volodymyr, Sacco, Simona, Schwedt, Todd J., Souza, Marcio Nattan P., Takizawa, Tsubasa, Tassorelli, Cristina, Terwindt, Gisela M., Thuraiaiyah, Janu, Togha, Mansoureh, Vandenbussche, Nicolas, Wang, Shuu-Jiun, Yu, Shengyuan   +40 more
core   +8 more sources